Lafayette Regional Health Center is proud to be part of the Sarah Cannon Cancer Institute HCA Midwest Health cancer network, providing local access to innovative clinical research trials, tumor profiling and genetic counseling; you can receive top cancer care in the comfort of your community hospital.
Sarah Cannon Cancer Institute offers a comprehensive array of diagnostic services such as minimally-invasive technology for diagnosing and treating breast lesions, as well as a range of cancer care services from screenings, cancer treatment and survivorship. The site is staffed by skilled oncology nurses who provide a wide variety of oncology and infusion services.
Free Risk Assessments
Eating right and exercising are great steps toward leading a healthy life, but did you know your family history, age, and countless other factors can still put you at risk for health problems? Try our free risk assessments below to estimate your personal risk of developing breast, colon or rectal cancer, and identify your different types of risk factors.
For more information, contact us at (660) 259-6884 or visit hcamidwest.com. In addition to comprehensive prevention tools, diagnostics, cutting-edge therapies and surgical treatments, Sarah Cannon Cancer Institute HCA Midwest Health also offers a cancer wellness program to help support you every step of the way.
The Lafayette Regional Health Center is in the process of becoming accredited by the American College of Surgeons, Commission on Cancer (CoC). The CoC publishes the Cancer Programs Practice Profile Reports (CP3R) which includes 6 measures for breast cancer.
The (CP³R) measurement helps facilities to:
- Ensure patients are treated according to recognized standards of care,
- Promote quality improvement activities, and
- Accurately compare clinical performance among CoC accredited cancer programs.
We compared our 2014 breast cases receiving hormone therapy to the most current CoC results of 2013:
|Accountability Measure||Lafayette Regional Health Center||Missouri||National|
|Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB –III hormone receptor positive breast cancer.||100%||94.3%||92.4%|
*The accountability measures were agreed upon by the NQF (National Quality Forum) who facilitated an agreement between the CoC (Commission on Cancer), ASCO (American Society for Conical Oncology) & NCCN (National Comprehensive Cancer Network).
Source: Commission on Cancer, National Cancer Database